在癌症治疗应用中准信号转换适配蛋白-2的潜力
Taiga Maemoto1, Yuto Sasaki1, Fumiya Okuyama1
1Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Exploration of targeted anti-tumor therapy
|May 15, 2024
概括
一种针对与BRK和EGFR的信号转换适配蛋白-2 (STAP-2) 相互作用的新型抑制剂显示,通过抑制瘤生长来治疗前列腺癌和肺癌具有前景.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现 药物发现
背景情况:
- 适应蛋白调节细胞内信号通路.
- 信号转换适配蛋白-2 (STAP-2) 与乳腺瘤激酶 (BRK) 和表皮生长因子受体 (EGFR) 相互作用.
- STAP-2/BRK失调与乳腺癌有关,而STAP-2在前列腺癌中稳定了EGFR,推动了扩散.
研究的目的:
- 研究抑制STAP-2与BRK和EGFR相互作用的治疗潜力.
- 评估一种旨在破坏STAP-2/BRK/EGFR结合的抑制剂.
- 在临床前癌症模型中评估抑制剂的疗效.
主要方法:
- 利用分子生物学技术研究STAP-2相互作用.
- 开发并测试了一种针对STAP-2结合域的抑制剂.
- 在异种移植模型中评估了抑制剂对蛋白相互作用,癌细胞增殖和瘤形成的影响.
主要成果:
- 抑制剂成功地阻止了STAP-2/EGFR相互作用和EGFR稳定.
- 抑制STAP-2/EGFR信号抑制了癌细胞的生长.
- 该抑制剂在前列腺癌和肺癌异种移植模型中的瘤形成减少方面表现出有效性.
结论:
- 抑制STAP-2/BRK/EGFR相互作用是癌症的可行治疗策略.
- 已识别的抑制剂是治疗前列腺癌和肺癌的有希望的候选者.
- 进一步开发STAP-2向可以提供新的癌症治疗选择.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K